期刊
DIABETES-METABOLISM RESEARCH AND REVIEWS
卷 37, 期 8, 页码 -出版社
WILEY
DOI: 10.1002/dmrr.3503
关键词
antidiabetic therapy; gastric inhibitory peptide; glucagon-like peptide 1; tirzepatide; type 2 diabetes
Tirzepatide is a dual GIP/GLP-1 receptor agonist with a long half-life, showing superiority in glycemic control and weight management in T2DM patients. While expected to enhance therapeutic options for T2DM, further data is needed for validation.
Tirzepatide is a dual gastric inhibitory peptide/glucagon-like peptide 1 (GIP/GLP-1) receptor agonist formulated as a synthetic linear peptide, based on the native GIP sequence. It has a prolonged half-life of 5 days, which enables once-weekly dosing. Studies have hitherto demonstrated its superiority in achieving optimal glycaemic control and body weight management, as compared with various agents used in the treatment of type 2 diabetes mellitus (T2DM), including GLP-1 receptor agonists. Thus, it is expected to enrich our therapeutic armamentarium in T2DM. However, further experience, notably longer follow-up data and information on cardiovascular effects, is still needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据